Health

Health Update – A new metric, the Body Roundness Index (BRI), is gaining traction as a more accurate indicator of health risks than the traditional body mass index (BMI). Body Mass Index, commonly abbreviated to BMI, calculates a person's health based on their height and weight. Despite its widespread use in health assessments, BMI has faced considerable criticism for its inability to accurately reflect an individual's health, particularly in those with high muscle mass. The limitations of BMI have become more apparent with individuals like Ilona Maher, an American Olympic rugby player. Despite a BMI of 30 that puts her…

Acadia Healthcare, one of the largest chains of psychiatric hospitals in the United States, has seen its revenues and stock price skyrocket in recent years. But a New York Times investigation reveals a disturbing truth: Part of that success comes from the exploitation of vulnerable patients. Retaining patients for profit, not to cure them The investigation found evidence that Acadia pressured patients to stay in their facilities, even when they were not medically necessary, to maximize insurance payouts. This practice violates involuntary detention laws, which are designed to protect those who pose a threat to themselves or others. Examples of…

Attention to health and well-being – The Food and Drug Administration (FDA) has issued a warning against using at-home chemical peels without the guidance of a professional. This article explores the potential risks involved and shares expert advice on how to use these products safely. Laura Messina, a 43-year-old user, experienced severe skin irritation after using an over-the-counter chemical peel to reduce dark spots. Her ordeal included painful red spots that persisted for days, eventually requiring professional dermatological care to manage the adverse effects. Chemical peels are designed to exfoliate the skin by removing its outer layers, promoting cell renewal…

Healthcare Response to Drug Shortages – In response to the ongoing challenges faced by patients and healthcare providers in securing adequate supplies of ADHD medications, the Drug Enforcement Administration (DEA) has announced a strategic increase in manufacturing limits for Vyvanse, a leading stimulant medication. This move is intended to alleviate shortages that have affected countless individuals across the nation. This article delves into the details of the DEA’s recent policy adjustment, authorizing a 24 percent increase in the production of lisdexamfetamine, commonly known as Vyvanse. This change is intended to meet growing domestic and international demand for the drug, especially…